Cargando…

iTRAQ-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy

Asthma is one of the most common childhood chronic diseases worldwide. Subcutaneous immunotherapy (SCIT) is commonly used in the treatment of house dust mite (HDM)-related asthma in children. However, the therapeutic mechanism of SCIT in asthma remains unclear. The present study aimed to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Jun, Zhong, Jia-Yong, Liao, Wang, Hu, Ruo, Chen, Liang, Wu, Xian-Jin, Liu, Shuang-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533450/
https://www.ncbi.nlm.nih.gov/pubmed/32901873
http://dx.doi.org/10.3892/mmr.2020.11472
_version_ 1783590136707022848
author Bai, Jun
Zhong, Jia-Yong
Liao, Wang
Hu, Ruo
Chen, Liang
Wu, Xian-Jin
Liu, Shuang-Ping
author_facet Bai, Jun
Zhong, Jia-Yong
Liao, Wang
Hu, Ruo
Chen, Liang
Wu, Xian-Jin
Liu, Shuang-Ping
author_sort Bai, Jun
collection PubMed
description Asthma is one of the most common childhood chronic diseases worldwide. Subcutaneous immunotherapy (SCIT) is commonly used in the treatment of house dust mite (HDM)-related asthma in children. However, the therapeutic mechanism of SCIT in asthma remains unclear. The present study aimed to investigate the molecular biomarkers associated with HDM-related asthma in asthmatic children prior and subsequent to SCIT treatment compared with those in healthy children via proteomic analysis. The study included a control group (30 healthy children), -Treatment group (30 children with HDM-related allergic asthma) and +Treatment group (30 children with HDM-related allergic asthma treated with SCIT). An isobaric labeling with relative and absolute quantification-based method was used to analyze serum proteome changes to detect differentially expressed proteins, while functional enrichment and protein-protein interaction network analysis were used to select candidate biomarkers. A total of 72 differentially expressed proteins were detected in the -Treatment, +Treatment and control groups. A total of 33 and 57 differentially expressed proteins were observed in the -Treatment vs. control and +Treatment vs. control groups, respectively. Through bioinformatics analysis, 5 candidate proteins [keratin 1 (KRT1), apolipoprotein B (APOB), fibronectin 1, antithrombin III (SERPINC1) and α-1-antitrypsin (SERPINA1)] were selected for validation by western blotting; among them, 4 proteins (KRT1, APOB, SERPINC1 and SERPINA1) showed robust reproducibility in asthma and control samples. This study illustrated the changes in proteome regulation following SCIT treatment for asthma. The 4 identified proteins may serve as potential biomarkers prior and subsequent to SCIT treatment, and help elucidate the molecular regulation mechanisms of SCIT to treat HDM-related asthma.
format Online
Article
Text
id pubmed-7533450
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-75334502020-10-07 iTRAQ-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy Bai, Jun Zhong, Jia-Yong Liao, Wang Hu, Ruo Chen, Liang Wu, Xian-Jin Liu, Shuang-Ping Mol Med Rep Articles Asthma is one of the most common childhood chronic diseases worldwide. Subcutaneous immunotherapy (SCIT) is commonly used in the treatment of house dust mite (HDM)-related asthma in children. However, the therapeutic mechanism of SCIT in asthma remains unclear. The present study aimed to investigate the molecular biomarkers associated with HDM-related asthma in asthmatic children prior and subsequent to SCIT treatment compared with those in healthy children via proteomic analysis. The study included a control group (30 healthy children), -Treatment group (30 children with HDM-related allergic asthma) and +Treatment group (30 children with HDM-related allergic asthma treated with SCIT). An isobaric labeling with relative and absolute quantification-based method was used to analyze serum proteome changes to detect differentially expressed proteins, while functional enrichment and protein-protein interaction network analysis were used to select candidate biomarkers. A total of 72 differentially expressed proteins were detected in the -Treatment, +Treatment and control groups. A total of 33 and 57 differentially expressed proteins were observed in the -Treatment vs. control and +Treatment vs. control groups, respectively. Through bioinformatics analysis, 5 candidate proteins [keratin 1 (KRT1), apolipoprotein B (APOB), fibronectin 1, antithrombin III (SERPINC1) and α-1-antitrypsin (SERPINA1)] were selected for validation by western blotting; among them, 4 proteins (KRT1, APOB, SERPINC1 and SERPINA1) showed robust reproducibility in asthma and control samples. This study illustrated the changes in proteome regulation following SCIT treatment for asthma. The 4 identified proteins may serve as potential biomarkers prior and subsequent to SCIT treatment, and help elucidate the molecular regulation mechanisms of SCIT to treat HDM-related asthma. D.A. Spandidos 2020-11 2020-09-01 /pmc/articles/PMC7533450/ /pubmed/32901873 http://dx.doi.org/10.3892/mmr.2020.11472 Text en Copyright: © Bai et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Bai, Jun
Zhong, Jia-Yong
Liao, Wang
Hu, Ruo
Chen, Liang
Wu, Xian-Jin
Liu, Shuang-Ping
iTRAQ-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy
title iTRAQ-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy
title_full iTRAQ-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy
title_fullStr iTRAQ-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy
title_full_unstemmed iTRAQ-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy
title_short iTRAQ-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy
title_sort itraq-based proteomic analysis reveals potential regulatory networks in dust mite-related asthma treated with subcutaneous allergen immunotherapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533450/
https://www.ncbi.nlm.nih.gov/pubmed/32901873
http://dx.doi.org/10.3892/mmr.2020.11472
work_keys_str_mv AT baijun itraqbasedproteomicanalysisrevealspotentialregulatorynetworksindustmiterelatedasthmatreatedwithsubcutaneousallergenimmunotherapy
AT zhongjiayong itraqbasedproteomicanalysisrevealspotentialregulatorynetworksindustmiterelatedasthmatreatedwithsubcutaneousallergenimmunotherapy
AT liaowang itraqbasedproteomicanalysisrevealspotentialregulatorynetworksindustmiterelatedasthmatreatedwithsubcutaneousallergenimmunotherapy
AT huruo itraqbasedproteomicanalysisrevealspotentialregulatorynetworksindustmiterelatedasthmatreatedwithsubcutaneousallergenimmunotherapy
AT chenliang itraqbasedproteomicanalysisrevealspotentialregulatorynetworksindustmiterelatedasthmatreatedwithsubcutaneousallergenimmunotherapy
AT wuxianjin itraqbasedproteomicanalysisrevealspotentialregulatorynetworksindustmiterelatedasthmatreatedwithsubcutaneousallergenimmunotherapy
AT liushuangping itraqbasedproteomicanalysisrevealspotentialregulatorynetworksindustmiterelatedasthmatreatedwithsubcutaneousallergenimmunotherapy